Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased as demand and projects for pharmaceutical and medical-related materials in the mass-production stage, semiconductor-related products, pharmaceuticals, and biotechnology remained firm, while the effect of higher revenue outweighed increases in fixed costs such as depreciation, personnel expenses, and maintenance and inspection costs.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥9,093 million (YoY +11.2%) |
| Operating profit | ¥1,024 million (YoY +32.7%) |
| Ordinary income | ¥1,028 million (YoY +10.7%) |
| Profit attributable to owners of the parent | ¥766 million (YoY +3.9%) |
| Net income per share | ¥99.02 |
| Operating Margin | 11.3％ |
| Equity ratio | End of the current fiscal period 65.1％ / End of previous period 67.1％ |
| Total assets | ¥21,644 million |
| Net assets | ¥14,080 million |
| Cash flows from operating activities | ¥2,262 million |
| Cash flows from investing activities | ¥-2,697 million |
| Cash flows from financing activities | ¥222 million |
| Cash and cash equivalents at end of period | ¥2,173 million |
| Full-year earnings forecast | Net Sales To be determined / Operating profit To be determined / Ordinary income To be determined / Net income To be determined |
| Annual Dividend Forecast | ¥33 → To be determined（To be determined） |
| Payout ratio | 33.3％ |
| Depreciation and amortization | ¥1,233,339 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of non-current assets / Amount ¥39 thousand / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount ¥2,988 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for individual investors and analysts) |
| Issued Shares at Period-End | 7,779,900 shares |
| Treasury Shares at Period-End | 38,580 shares |
| Factors Behind Changes in Business Performance | Revenue increased as demand and projects for pharmaceutical and medical-related materials in the mass-production stage, semiconductor-related products, pharmaceuticals, and biotechnology remained firm, while the effect of higher revenue outweighed increases in fixed costs such as depreciation, personnel expenses, and maintenance and inspection costs. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Demand and projects for pharmaceutical and medical-related materials in the mass-production stage, semiconductor-related products, pharmaceuticals, and biotechnology remained firm, and the effect of higher revenue outweighed increases in fixed costs such as depreciation, personnel expenses, and maintenance and inspection costs. The reason for leaving the full-year forecast undetermined is the risk of supply constraints accompanying heightened tensions in the Middle East and surging resource and raw material prices.